KR20230014850A - 암을 치료하기 위한, 화학 요법 및 방사선 요법과의 양극성 트랜스 카로티노이드의 용도 - Google Patents

암을 치료하기 위한, 화학 요법 및 방사선 요법과의 양극성 트랜스 카로티노이드의 용도 Download PDF

Info

Publication number
KR20230014850A
KR20230014850A KR1020237001272A KR20237001272A KR20230014850A KR 20230014850 A KR20230014850 A KR 20230014850A KR 1020237001272 A KR1020237001272 A KR 1020237001272A KR 20237001272 A KR20237001272 A KR 20237001272A KR 20230014850 A KR20230014850 A KR 20230014850A
Authority
KR
South Korea
Prior art keywords
cancer
chemotherapy
tsc
administering
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020237001272A
Other languages
English (en)
Korean (ko)
Inventor
존 엘. 그레이너
Original Assignee
디퓨젼 파마슈티컬즈 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 디퓨젼 파마슈티컬즈 엘엘씨 filed Critical 디퓨젼 파마슈티컬즈 엘엘씨
Publication of KR20230014850A publication Critical patent/KR20230014850A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1077—Beam delivery systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237001272A 2016-03-24 2017-03-23 암을 치료하기 위한, 화학 요법 및 방사선 요법과의 양극성 트랜스 카로티노이드의 용도 Withdrawn KR20230014850A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662312988P 2016-03-24 2016-03-24
US62/312,988 2016-03-24
KR1020187030594A KR102489034B1 (ko) 2016-03-24 2017-03-23 암을 치료하기 위한, 화학 요법 및 방사선 요법과의 양극성 트랜스 카로티노이드의 용도
PCT/US2017/023844 WO2017165667A1 (en) 2016-03-24 2017-03-23 Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187030594A Division KR102489034B1 (ko) 2016-03-24 2017-03-23 암을 치료하기 위한, 화학 요법 및 방사선 요법과의 양극성 트랜스 카로티노이드의 용도

Publications (1)

Publication Number Publication Date
KR20230014850A true KR20230014850A (ko) 2023-01-30

Family

ID=59900880

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020237001272A Withdrawn KR20230014850A (ko) 2016-03-24 2017-03-23 암을 치료하기 위한, 화학 요법 및 방사선 요법과의 양극성 트랜스 카로티노이드의 용도
KR1020187030594A Active KR102489034B1 (ko) 2016-03-24 2017-03-23 암을 치료하기 위한, 화학 요법 및 방사선 요법과의 양극성 트랜스 카로티노이드의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187030594A Active KR102489034B1 (ko) 2016-03-24 2017-03-23 암을 치료하기 위한, 화학 요법 및 방사선 요법과의 양극성 트랜스 카로티노이드의 용도

Country Status (8)

Country Link
US (2) US11185523B2 (enExample)
EP (1) EP3432929A4 (enExample)
JP (2) JP7032320B2 (enExample)
KR (2) KR20230014850A (enExample)
CN (2) CN115089569A (enExample)
CA (1) CA3018550A1 (enExample)
IL (1) IL261922A (enExample)
WO (1) WO2017165667A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA95903C2 (ru) 2005-02-24 2011-09-26 Дифьюжен Фармасьютикалз Ллк Транс-каротиноиды, их синтез, лекарственная форма и применение
KR101875843B1 (ko) 2009-06-22 2018-07-06 디퓨젼 파마슈티컬즈 엘엘씨 확산 촉진 화합물 및 그 화합물 단독 또는 혈전 용해제와 합쳐진 화합물의 용도
CN105287473A (zh) 2010-06-02 2016-02-03 扩散药品有限公司 包含双极性反式类胡萝卜素的组合物及其应用
WO2017165667A1 (en) * 2016-03-24 2017-09-28 Diffusion Pharmaceuticals Llc Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer
JP7355394B2 (ja) * 2018-05-03 2023-10-03 エル．イー．エー．エフ． ホールディングス グループ エルエルシー カロテノイド組成物およびその使用
WO2022025998A1 (en) * 2020-07-27 2022-02-03 L.E.A.F. Holdings Group Llc Trans-crocetin compositions and treatment regimens
WO2022150716A1 (en) * 2021-01-10 2022-07-14 Diffusion Pharmaceuticals Llc Methods of treating wounds and burns
AU2022274217A1 (en) * 2021-05-10 2023-11-30 L.E.A.F. Holdings Group Llc Methods and compositions for treating aging and chronic disease
US20240316000A1 (en) * 2021-06-29 2024-09-26 Diffusion Pharmaceuticals Llc Methods of treatment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060276372A1 (en) 2005-03-09 2006-12-07 Lockwood Samuel F Carotenoids, carotenoid analogs, or carotenoid derivatives for the treatment of proliferative disorders
US20110196038A1 (en) 2002-02-25 2011-08-11 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2948748A (en) 1960-08-09 Esters thereof
US2175843A (en) 1936-06-26 1939-10-10 Winthrop Chem Co Inc Polyene carboxylic acids and esters and manufacture thereof
CH468330A (de) 1966-01-28 1969-02-15 Hoffmann La Roche Verfahren zur Herstellung von isoprenoiden Verbindungen
US3489806A (en) 1967-01-19 1970-01-13 Hoffmann La Roche Isoprenoid compounds and a process for producing the same
JPS4514114Y1 (enExample) 1969-07-17 1970-06-15
CH522572A (de) 1969-10-31 1972-06-30 Hoffmann La Roche Verfahren zur Herstellung von Polyenverbindungen
US3853993A (en) 1973-05-01 1974-12-10 Univ Virginia Process for increasing oxygen diffusivity and method for treating atherosclerosis
US3788468A (en) 1973-05-01 1974-01-29 Univ Virginia Process for increasing oxygen diffusivity
US3853933A (en) 1974-01-14 1974-12-10 Gen Electric Continuous process for producing polysiloxane oils utilizing a carbon black catalyst
DE2505869C3 (de) 1975-02-12 1978-05-18 Basf Ag, 6700 Ludwigshafen Verfahren zur Herstellung von symmetrischen Carotinoiden
US3965261A (en) 1975-04-29 1976-06-22 University Of Virginia Method for treating papillomas
US3975519A (en) 1975-06-09 1976-08-17 University Of Virginia Method for increasing the oxygen partial pressure in the bloodstream of mammals
US4070460A (en) 1975-11-10 1978-01-24 University Of Virginia Patents Foundation Method for treating cerebral edema
US4009270A (en) 1975-11-21 1977-02-22 The University Of Virginia Method for treating spinal cord injury
US4038144A (en) 1976-04-19 1977-07-26 The University Of Virginia Method of increasing fermentation yields
US4046880A (en) 1976-04-20 1977-09-06 The University Of Virginia Method of treating hypertension
US4099270A (en) 1977-02-16 1978-07-11 Jabour Richard J Slip-on rubber gloves
US4216211A (en) 1977-10-31 1980-08-05 The Procter & Gamble Company Therapeutic composition
US4176179A (en) 1978-04-17 1979-11-27 The University Of Virginia Alumni Patents Foundation Method for treating arthritis
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4699664A (en) 1985-05-01 1987-10-13 Nestec S.A. Stabilized natural pigment complexes
US5032613A (en) 1986-02-12 1991-07-16 W. Keith R. Watson Method and composition for treating arthritis
JP3161417B2 (ja) 1986-04-28 2001-04-25 日本鋼管株式会社 耐孔食性に優れた２相ステンレス鋼
JPH0661211B2 (ja) 1986-08-29 1994-08-17 花王株式会社 パン用改質剤、パン生地及びパンの製造方法
US4781676A (en) 1987-02-20 1988-11-01 Air Products And Chemicals, Inc. Interstitial administration of perfluorochemical emulsions for reoxygenation of hypoxic tumor cells
US5811119A (en) 1987-05-19 1998-09-22 Board Of Regents, The University Of Texas Formulation and use of carotenoids in treatment of cancer
US5084274A (en) 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US5472946A (en) 1988-04-08 1995-12-05 Peck; James V. Transdermal penetration enhancers
GB8822147D0 (en) 1988-09-21 1988-10-26 Ciba Geigy Ag Pharmaceutically active combination
FR2647343B1 (fr) 1989-05-24 1994-05-06 Rhone Poulenc Sante Nouvelle forme pharmaceutique poreuse et sa preparation
US5053240A (en) 1989-10-24 1991-10-01 Kalamazoo Holdings, Inc. Norbixin adducts with water-soluble or water-dispersible proteins or branched-chain or cyclic polysaccharides
JPH04264020A (ja) 1991-02-18 1992-09-18 Yamanouchi Pharmaceut Co Ltd 安定な凍結乾燥製剤
US5107030A (en) 1991-03-04 1992-04-21 Loyola University Of Chicago Method of making 2,7-dimethyl-2,4,6-octatrienedial and derivatives thereof
JP3176716B2 (ja) 1991-06-21 2001-06-18 武田薬品工業株式会社 溶解性が向上した難水溶性薬物組成物
JP2977961B2 (ja) 1991-07-26 1999-11-15 株式会社資生堂 化粧料
JPH06248193A (ja) 1993-02-25 1994-09-06 Ensuiko Sugar Refining Co Ltd クロセチン含有着色料
IL110139A0 (en) 1993-06-28 1994-10-07 Howard Foundation Pharmaceutically-active antioxidants
JPH0723736A (ja) 1993-06-30 1995-01-27 Taishiyoo Technos:Kk カロチノイド色素の可溶化方法
JP2704356B2 (ja) 1994-02-08 1998-01-26 正和薬品株式会社 脳機能改善剤
JPH07291854A (ja) 1994-04-26 1995-11-07 Tanabe Seiyaku Co Ltd 溶解性の改善された医薬品製剤
US5576287A (en) 1994-04-29 1996-11-19 Wake Forest University Method for treating acute renal disease and failure
GB2290964A (en) 1994-07-08 1996-01-17 Arto Olavi Urtti Transdermal drug delivery system
US6060511A (en) 1995-10-05 2000-05-09 Gainer; John L. Trans-sodium crocetinate, methods of making and methods of use thereof
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
RU2107496C1 (ru) 1997-02-10 1998-03-27 Российская медицинская академия последипломного образования Министерства здравоохранения РФ Способ лечения диабетической ангиопатии
JPH1119261A (ja) 1997-07-01 1999-01-26 Takenaka Komuten Co Ltd 低圧トレーニング施設
JPH1129466A (ja) 1997-07-09 1999-02-02 Lion Corp 水性皮膚外用剤
US6391336B1 (en) 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
US6150561A (en) 1997-10-03 2000-11-21 Roche Vitamins Inc. Method of making carotenoids
JPH11209642A (ja) 1998-01-27 1999-08-03 Taito Kk アナトー色素製剤及びその製造方法
US6235311B1 (en) 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
JP2000007570A (ja) 1998-06-24 2000-01-11 Hayashibara Biochem Lab Inc 抗内分泌障害剤
CN1243120A (zh) 1998-07-23 2000-02-02 云南省烟草工业研究所 类胡萝卜素诱导剂2－二氨基乙基－4－甲苯基醚盐的合成方法及其在烟草中的应用
MA25590A1 (fr) 1998-09-14 2002-12-31 Inhale Therapeutic Syst Agent actif de delivraison de poudre seche
BE1012495A3 (fr) 1999-03-02 2000-11-07 Messadek Jallal La glycine-betaine pour son usage antithrombotique.
AU6912500A (en) 1999-08-25 2001-03-19 Gmp Companies, Inc. Enhanced oxygen delivery in mammals, methods and reagents related thereto
GB2353934A (en) 1999-09-09 2001-03-14 British Sugar Plc Nutritional compositions comprising trehalose for persons suffering from diabetes
JP2001302517A (ja) 2000-04-24 2001-10-31 Tokyo Univ Of Pharmacy & Life Science 脳浮腫の予防治療薬
CA2355814C (en) 2000-09-14 2010-06-29 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Pharmaceutical composition for ophthalmic use
EP1269994A3 (en) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
JP2003201238A (ja) 2001-12-03 2003-07-18 Yamanouchi Pharmaceut Co Ltd 脳梗塞治療用医薬組成物
WO2003059270A2 (en) 2002-01-15 2003-07-24 Eli Lilly And Company Method for reducing morbidity and mortality in critically ill patients
BE1015608A6 (fr) 2003-07-15 2005-06-07 Messadek Jallal Traitement des arterites.
WO2003072734A2 (en) 2002-02-25 2003-09-04 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
US20030180281A1 (en) 2002-03-11 2003-09-25 Bott Richard R. Preparations for topical skin use and treatment
US20030180282A1 (en) 2002-03-25 2003-09-25 Victor Serebruany Method of treatment of thrombotic events
RU2226096C1 (ru) 2002-07-01 2004-03-27 Санкт-Петербургский государственный научно-исследовательский институт скорой помощи им. И.И.Джанелидзе Способ лечения последствий тканевой гипоксии у пациентов в критическом состоянии
AU2003258890A1 (en) 2002-07-04 2004-01-23 Poltec As Complexes of cyclodextrins and carotenoids
US7521584B2 (en) 2002-07-29 2009-04-21 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of disease
MXPA05001202A (es) 2002-07-29 2005-11-23 Hawaii Biotech Inc Analogos carotenoides estructurales para la inhibicion y mejora de la enfermedad.
US7001893B2 (en) 2002-10-28 2006-02-21 Council Of Scientific And Industrial Research Inclusion complex of Rifampicin, an anti-tubercular drug, with β-cyclodextrin or 2-hydroxypropyl β-cyclodextrin and a process thereof
DE10254809A1 (de) 2002-11-22 2004-06-03 Basf Ag Verfahren zur Herstellung von Carotinoiden
WO2004049095A2 (en) 2002-11-25 2004-06-10 Jallal Messadek Betaine and salicylic acid compositions
US20040109920A1 (en) 2002-12-04 2004-06-10 Bioactives Llc Coated carotenoid cyclodextrin complexes
US20070166339A1 (en) 2003-04-18 2007-07-19 Bioderm Research Skin Whitening Methods and Compositions Based on Zeolite - Active Oxygen Donor Complexes
EP1621199B8 (en) 2003-04-18 2011-01-19 Advanced Medicine Research Institute Remedies for diseases to be applied to eye
BRPI0409865A (pt) 2003-05-02 2006-05-16 Paion Deutschland Gmbh injeção intravenosa de ativadores de plasminogênio não neurotóxicos para o tratamento do ataque de apoplexia
JP2005053841A (ja) 2003-08-05 2005-03-03 Kyouto Biomedical Science:Kk 皮膚外用剤
EP1667954B1 (en) 2003-08-25 2018-11-14 Diffusion Pharmaceuticals LLC Bipolar trans carotenoid salts and their uses
RU2265434C2 (ru) 2003-09-30 2005-12-10 Государственное учреждение Научно-исследовательский Институт Общей реаниматологии Российской Академии Медицинских Наук (ГУ НИИ ОР РАМН) Способ лечения острого респираторного дистресс-синдрома
RU2256446C1 (ru) 2003-10-22 2005-07-20 Государственное учреждение Межотраслевой научно-технический комплекс "Микрохирургия глаза" им. акад. С.Н. Федорова Способ профилактики метастазов после хирургического удаления внутриглазных новообразований
US7446101B1 (en) 2003-12-12 2008-11-04 Bioactives, Llc Bioavailable carotenoid-cyclodextrin formulations for soft-gels and other encapsulation systems
AU2005251463A1 (en) 2004-06-14 2005-12-22 Zoser B. Salama Anti-cancer composition comprising proline or its derivatives and an anti-tumour antibody
JP4514114B2 (ja) 2004-06-18 2010-07-28 ヤマハ発動機株式会社 コイル可動形リニアモータおよび単軸ロボット
US20070292523A1 (en) 2004-09-27 2007-12-20 Joey Moodley Dihydropyrimidine Formulations
US20060088905A1 (en) 2004-10-01 2006-04-27 Lockwood Samuel F Methods for the synthesis of zeazanthin
WO2006083780A2 (en) 2005-01-31 2006-08-10 Mylan Laboratories, Inc. Glucuronidated nebivolol
UA95903C2 (ru) * 2005-02-24 2011-09-26 Дифьюжен Фармасьютикалз Ллк Транс-каротиноиды, их синтез, лекарственная форма и применение
WO2006091924A2 (en) 2005-02-24 2006-08-31 Regents Of The University Of Minnesota Producing carotenoids
AU2006219152B2 (en) 2005-03-04 2011-02-24 Sucampo Ag Method and composition for treating peripheral vascular diseases
US20060281724A1 (en) 2005-06-08 2006-12-14 Loria Roger M Methods for Treating Shock
JP2006342108A (ja) 2005-06-09 2006-12-21 Mitsubishi Chemicals Corp アミロスフェロイドにより発生する疾患の予防治療剤
EP2258441A3 (en) 2005-09-02 2011-09-21 Intercell USA, Inc. Devices for transcutaneous delivery of vaccines and transdermal delivery of drugs
US20070135521A1 (en) 2005-12-14 2007-06-14 Yamaha Hatsudoki Kabushiki Kaisha Agent for Preventing Metabolic Syndrome
ITMI20052486A1 (it) 2005-12-23 2007-06-24 Italiana Sint Spa Procedimento di sintesi di intermedi per la preparazione di astaxantina
AU2006341188A1 (en) 2006-03-24 2007-10-04 Ian Simon Tracton Stable packaged dosage form and process therefor
CN100571707C (zh) 2006-07-24 2009-12-23 凌沛学 含有海藻糖的关节腔内注射给药制剂
TWI439282B (zh) 2006-08-29 2014-06-01 Genentech Inc 以血栓溶解劑治療中風之方法
EP2198869B1 (en) 2007-02-23 2015-09-16 Next 21 K.K. Trehalose for the treatment or prevention of vasospasm
EP3483140A1 (en) 2007-04-13 2019-05-15 Diffusion Pharmaceuticals LLC Use of bipolar trans carotenoids as a pretreatment and in the treatment of peripheral vascular disease
PL2152250T3 (pl) 2007-05-07 2020-06-15 Evonik Röhm Gmbh Stałe postaci dawkowania zawierające otoczkę dojelitową o przyspieszonym uwalnianiu leku
EA201070544A1 (ru) 2007-10-31 2010-12-30 Диффьюжн Фармасьютикалз Ллс Новый класс терапевтических веществ, усиливающих диффузию низкомолекулярных соединений
US20090118227A1 (en) 2007-11-07 2009-05-07 Bristol-Myers Squibb Company Carotenoid-containing compositions and methods
WO2009111688A2 (en) 2008-03-06 2009-09-11 Wisconsin Alumni Research Foundation All-trans retinoid esters as active pharmaceutical ingredients, oral and topical dosage form compositions thereof, and methods of treating skin conditions thereof
KR101875843B1 (ko) 2009-06-22 2018-07-06 디퓨젼 파마슈티컬즈 엘엘씨 확산 촉진 화합물 및 그 화합물 단독 또는 혈전 용해제와 합쳐진 화합물의 용도
JP2010090151A (ja) 2009-12-09 2010-04-22 Diffusion Pharmaceuticals Llc 双極性トランスカロテノイド塩及びそれらの使用
CN105287473A (zh) 2010-06-02 2016-02-03 扩散药品有限公司 包含双极性反式类胡萝卜素的组合物及其应用
WO2017165667A1 (en) 2016-03-24 2017-09-28 Diffusion Pharmaceuticals Llc Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110196038A1 (en) 2002-02-25 2011-08-11 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
US20060276372A1 (en) 2005-03-09 2006-12-07 Lockwood Samuel F Carotenoids, carotenoid analogs, or carotenoid derivatives for the treatment of proliferative disorders

Also Published As

Publication number Publication date
WO2017165667A1 (en) 2017-09-28
WO2017165667A9 (en) 2018-05-11
US20190083439A1 (en) 2019-03-21
CA3018550A1 (en) 2017-09-28
EP3432929A1 (en) 2019-01-30
CN109152839A (zh) 2019-01-04
KR102489034B1 (ko) 2023-01-13
JP2019513134A (ja) 2019-05-23
CN115089569A (zh) 2022-09-23
EP3432929A4 (en) 2019-11-27
JP2022081527A (ja) 2022-05-31
IL261922A (en) 2018-10-31
JP7032320B2 (ja) 2022-03-08
US11185523B2 (en) 2021-11-30
US20220265592A1 (en) 2022-08-25
KR20190013715A (ko) 2019-02-11

Similar Documents

Publication Publication Date Title
KR102489034B1 (ko) 암을 치료하기 위한, 화학 요법 및 방사선 요법과의 양극성 트랜스 카로티노이드의 용도
ES2690174T3 (es) Nanopartícula que comprende rapamicina y albúmina como agente antineoplásico
ES2678448T3 (es) Combinaciones y modos de administración de agentes terapéuticos y terapia combinada
MXPA05001430A (es) Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas.
EP3151864B1 (en) Combination therapy comprising a liposomal prodrug of mitomycin c and radiotherapy
AU2013204187B2 (en) Nanoparticle comprising rapamycin and albumin as anticancer agent
RU2396960C2 (ru) Комбинированная противоопухолевая терапия и фармацевтические композиции для нее
TW201717926A (zh) 用於治療尤文氏家族腫瘤(ewing family tumors)的組成物及方法
Parnell et al. Principles of cancer treatment by chemotherapy
WO2025070603A1 (ja) 血液がんの新規併用療法
WO2006095270A1 (en) Combination anticancer therapy or om-174 and pharmaceutical compositions therefor
KR20050037572A (ko) 이알비 비 키나아제 억제제와 항종양 요법의 치료적 조합
ZA200502759B (en) Combination therapy with gemcitabine and ZD6126
HK1173977A (en) Nanoparticle comprising rapamycin and albumin as anticancer agent
HK1173975A (en) Nanoparticle comprising rapamycin and albumin as anticancer agent

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203